BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy.

BOUCHALOVÁ, K., M. SVOBODA, G. KHARAISHVILI, J. VRBKOVÁ, J. BOUCHAL, R. TROJANEC, V. KOUDELÁKOVÁ, L. RADOVÁ, K. CWIERTKA, M. HAJDÚCH, Z. KOLÁŘ
BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy. Tumor Biology. 2015, 36(6), 4243-52, ISSN: 1010-4283, PMID: 25616695,